v3.26.1
Segment Reporting
 6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Segment Reporting

17. Segment Reporting

 

The Company manages its business activities on a consolidated basis and operate as a single operating and reportable segment: Syndax Pharmaceuticals. The Company primarily derives revenue in the United States through milestone revenue and product sales on the approved products, Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr). The accounting policies of the segment are the same as those described in Note 3 – Summary of Significant Accounting Policies.
 

To assess performance, the Company’s Chief Operating Decision Maker, or CODM, Michael Metzger, uses consolidated net loss as the segment’s measure of segment profit or loss. The CODM uses net loss in the budget and forecasting process and considers budget-to actual variances on a quarterly basis when making decisions about the allocation of operating and capital resources.

The following table provides the operating financial results of our biopharmaceutical cancer therapeutics segment:

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

June 30, 2026

 

 

 

 

 

 

 

 

 

 

 

 

Total Revenue

 

$

72,788

 

 

$

37,958

 

 

$

137,652

 

 

$

57,753

 

Less: Significant and other segment expenses

 

 

 

 

 

 

 

 

 

 

 

 

Cost of product sales

 

 

3,208

 

 

 

1,279

 

 

 

5,841

 

 

 

2,164

 

Research and development expenses

 

 

 

 

 

 

 

 

 

 

 

 

Revumenib-related costs

 

 

35,493

 

 

 

28,155

 

 

 

61,218

 

 

 

48,960

 

Axatilimab-related costs

 

 

8,682

 

 

 

9,053

 

 

 

18,315

 

 

 

28,764

 

Other R&D programs

 

 

1,043

 

 

 

1,826

 

 

 

1,205

 

 

 

2,747

 

Personnel cost and other expenses

 

 

18,308

 

 

 

18,997

 

 

 

37,606

 

 

 

35,528

 

General and administrative expenses

 

 

 

 

 

 

 

 

 

 

 

 

Commercial-related expenses

 

 

9,869

 

 

 

9,914

 

 

 

17,590

 

 

 

20,739

 

Personnel cost and other expenses

 

 

16,298

 

 

 

19,307

 

 

 

32,999

 

 

 

38,389

 

Other SG&A expenses

 

 

5,868

 

 

 

4,993

 

 

 

11,008

 

 

 

9,405

 

Stock-based compensation

 

 

14,014

 

 

 

13,787

 

 

 

26,067

 

 

 

24,167

 

Royalty interest expense

 

 

12,119

 

 

 

7,854

 

 

 

23,965

 

 

 

15,903

 

Convertible note interest expense

 

 

555

 

 

 

—

 

 

 

555

 

 

 

—

 

Interest expense (income), net

 

 

(3,744

)

 

 

(5,946

)

 

 

(7,305

)

 

 

(13,127

)

Other expense, net

 

 

438

 

 

 

586

 

 

 

624

 

 

 

807

 

Segment net loss

 

$

(49,363

)

 

$

(71,847

)

 

$

(92,036

)

 

$

(156,693

)